West Pharmaceutical Services Stock Performance
| WST Stock | USD 224.91 0.89 0.39% |
The firm maintains a market beta of -0.14, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning West Pharmaceutical are expected to decrease at a much lower rate. During the bear market, West Pharmaceutical is likely to outperform the market. At this point, West Pharmaceutical has a negative expected return of -0.47%. Please make sure to check out West Pharmaceutical's value at risk and rate of daily change , to decide if West Pharmaceutical performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days West Pharmaceutical Services has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (2.63) | Five Day Return (0.96) | Year To Date Return (31.24) | Ten Year Return 291.61 | All Time Return 20.2 K |
Forward Dividend Yield 0.0037 | Payout Ratio | Last Split Factor 2:1 | Forward Dividend Rate 0.84 | Dividend Date 2025-05-07 |
1 | abrdn plc Sells 6,525 Shares of West Pharmaceutical Services, Inc. | 02/05/2025 |
| West Pharmaceutical dividend paid on 11th of February 2025 | 02/11/2025 |
2 | West Pharmaceutical Services, Inc. Shares Bought by Fiera Capital Corp | 02/13/2025 |
3 | Acquisition by Eric Green of 5256 shares of West Pharmaceutical subject to Rule 16b-3 | 02/18/2025 |
4 | West Pharmaceutical Services Inc s Winning Formula Financial Metrics and Competitive ... | 02/27/2025 |
5 | Insider Trading | 02/28/2025 |
6 | Ascend Advanced Therapies Appoints John Chiminski as Chair and Karen Flynn as Independent Director | 03/05/2025 |
7 | MT Bank Corp Sells 1,351 Shares of West Pharmaceutical Services, Inc. | 03/06/2025 |
8 | Florida Rep. Jared Moskowitz Sold Up to 15K Worth of West Pharmaceutical Servs Stock | 03/07/2025 |
9 | West Pharmaceutical Services, Inc. Shares Bought by Inspire Advisors LLC | 03/12/2025 |
10 | Is West Pharmaceutical Services Stock Underperforming the SP 500 - Nasdaq | 03/21/2025 |
11 | Unpacking Q4 Earnings West Pharmaceutical Services In The Context Of Other Drug Development Inputs Services Stocks | 03/25/2025 |
| Begin Period Cash Flow | 853.9 M |
West |
West Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 33,322 in West Pharmaceutical Services on December 26, 2024 and sell it today you would lose (10,968) from holding West Pharmaceutical Services or give up 32.92% of portfolio value over 90 days. West Pharmaceutical Services is generating negative expected returns assuming volatility of 5.3235% on return distribution over 90 days investment horizon. In other words, 47% of stocks are less volatile than West, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
West Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for West Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as West Pharmaceutical Services, and traders can use it to determine the average amount a West Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0885
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | WST |
Estimated Market Risk
| 5.32 actual daily | 47 53% of assets are more volatile |
Expected Return
| -0.47 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average West Pharmaceutical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of West Pharmaceutical by adding West Pharmaceutical to a well-diversified portfolio.
West Pharmaceutical Fundamentals Growth
West Stock prices reflect investors' perceptions of the future prospects and financial health of West Pharmaceutical, and West Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on West Stock performance.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0993 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 16.14 B | ||||
| Shares Outstanding | 72.29 M | ||||
| Price To Earning | 40.71 X | ||||
| Price To Book | 6.09 X | ||||
| Price To Sales | 5.79 X | ||||
| Revenue | 2.89 B | ||||
| Gross Profit | 998.5 M | ||||
| EBITDA | 743.9 M | ||||
| Net Income | 492.7 M | ||||
| Cash And Equivalents | 894.3 M | ||||
| Cash Per Share | 9.85 X | ||||
| Total Debt | 302.3 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 3.80 X | ||||
| Book Value Per Share | 37.10 X | ||||
| Cash Flow From Operations | 653.4 M | ||||
| Earnings Per Share | 6.68 X | ||||
| Market Capitalization | 16.76 B | ||||
| Total Asset | 3.64 B | ||||
| Retained Earnings | 3.96 B | ||||
| Working Capital | 987.7 M | ||||
| Current Asset | 673.7 M | ||||
| Current Liabilities | 314.3 M | ||||
About West Pharmaceutical Performance
Assessing West Pharmaceutical's fundamental ratios provides investors with valuable insights into West Pharmaceutical's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the West Pharmaceutical is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 72.63 | 52.04 | |
| Return On Tangible Assets | 0.14 | 0.15 | |
| Return On Capital Employed | 0.18 | 0.10 | |
| Return On Assets | 0.14 | 0.14 | |
| Return On Equity | 0.18 | 0.10 |
Things to note about West Pharmaceutical performance evaluation
Checking the ongoing alerts about West Pharmaceutical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for West Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| West Pharmaceutical generated a negative expected return over the last 90 days | |
| West Pharmaceutical has high historical volatility and very poor performance | |
| Over 97.0% of the company outstanding shares are owned by institutional investors | |
| On 11th of February 2025 West Pharmaceutical paid $ 0.21 per share dividend to its current shareholders | |
| Latest headline from finance.yahoo.com: Unpacking Q4 Earnings West Pharmaceutical Services In The Context Of Other Drug Development Inputs Services Stocks |
- Analyzing West Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether West Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining West Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating West Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of West Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of West Pharmaceutical's stock. These opinions can provide insight into West Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for West Stock Analysis
When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.